Nouscom Raises 120 Million Euros for Cancer Interception
Nouscom closed an oversubscribed EUR 120 million ($135 million) Series D to finance a global registration-enabling study of NOUS-209 in Lynch syndrome carriers. The financing is strategically material because it moves a shared-neoantigen vaccine…
